Reduction in ^99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy

References

• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi:10.1038/s41582-019-0210-4.
   PubMed Web of Science ®Google Scholar
• Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826–1834. doi:10.1093/eurheartj/ehv583.
   PubMed Web of Science ®Google Scholar
• Auer-Grumbach M, Rettl R, Ablasser K, et al. Hereditary attr amyloidosis in Austria: prevalence and epidemiological hot spots. J Clin Med. 2020;9(7):1–11. doi:10.3390/jcm9072234.
   Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Obici L, Berk JL, González-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153–162. doi:10.1080/13506129.2020.1730790.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi:10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study. Circulation. 2019;139(4):431–443. doi:10.1161/CIRCULATIONAHA.118.035831.
   PubMed Web of Science ®Google Scholar
• Dasgupta NR, Rissing SM, Smith J, et al. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27(1):52–58. doi:10.1080/13506129.2019.1685487.
   PubMed Web of Science ®Google Scholar
• Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189–199. doi:10.1016/j.jcmg.2020.07.043.
   PubMed Web of Science ®Google Scholar
• Armstrong IS, Hoffmann SA. Activity concentration measurements using a conjugate gradient (siemens xSPECT) reconstruction algorithm in SPECT/CT. Nucl Med Commun. 2016;37(11):1212–1217. doi:10.1097/MNM.0000000000000586.
   PubMed Web of Science ®Google Scholar
• Delcroix O, Robin P, Gouillou M, et al. A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases. EJNMMI Res. 2018;8(1):14. doi:10.1186/s13550-018-0367-7.
   PubMedGoogle Scholar
• Scully PR, Morris E, Patel KP, et al. DPD quantification in cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1353–1363. doi:10.1016/j.jcmg.2020.03.020.
   PubMed Web of Science ®Google Scholar
• Wollenweber T, Rettl R, Kretschmer-Chott E, et al. In vivo quantification of myocardial amyloid deposits in patients with suspected transthyretin-related amyloidosis (ATTR). J Clin Med. 2020;9(11):1–13. doi:10.3390/jcm9113446.
   Web of Science ®Google Scholar
• Rettl R, Wollenweber T, Duca F, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24(8):jead030–1030. doi:10.1093/ehjci/jead030.
   Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612.
   PubMed Web of Science ®Google Scholar
• Bonderman D, Pölzl G, Ablasser K, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23-24):742–761. doi:10.1007/s00508-020-01781-z.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084. doi:10.1016/j.jacc.2005.05.073.
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins de Silva A, Lopes Lima JR, et al. Forty years of experience with type I amyloid neuropathy: review of 483 cases. Excerpta Medica. 1980;88–98.
   Google Scholar
• Lockwood PA, Le VH, O'Gorman MT, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(7):849–854. doi:10.1002/cpdd.789.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/nejmoa1805689.
   PubMed Web of Science ®Google Scholar
• Guidelines for the Six-Minute walk TestATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):1–7. doi:10.1164/ajrccm.166.1.at1102.
   PubMed Web of Science ®Google Scholar
• Vija A. Introduction to xSPECT* technology: evolving multi-modal SPECT to become context-based and quantitative. White Pap. 2013;1–28.
   Google Scholar
• Ramsay SC, Lindsay K, Fong W, et al. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging. 2018;2(1):17. doi:10.1186/s41824-018-0035-1.
   PubMedGoogle Scholar
• Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults. J Am Soc Echocardiogr. 2010;23(7):685–713. doi:10.1016/j.echo.2010.05.010.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270. doi:10.1093/ehjci/jev014.
   PubMed Web of Science ®Google Scholar
• Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging from histological validation to clinical implication. JACC Cardiovasc Imaging. 2016;9(1):14–23. doi:10.1016/j.jcmg.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Kramer CM, Barkhausen J, Bucciarelli-Ducci C, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020;22(1):17. doi:10.1186/s12968-020-00607-1.
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Moon JC, Ferreira VM, et al. Cardiac magnetic resonance T1 mapping in cardiac amyloidosis. J Cardiovasc Magn Reson. 2017;19(1):75. doi:10.1186/s12968-017-0389-8.
   PubMedGoogle Scholar
• Sperry BW, Orme NM, Case JA, et al. Complete resolution of technetium pyrophosphate uptake after treatment of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2023;16(6):e014954. doi:10.1161/circimaging.122.014954.
   PubMed Web of Science ®Google Scholar
• Löfbacka V, Axelsson J, Pilebro B, et al. Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(6):1822–1832. doi:10.1007/s00259-020-05144-8.
   PubMed Web of Science ®Google Scholar
• Miller RJH, Cadet S, Mah D, et al. Diagnostic and prognostic value of technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2021;28(5):1835–1845. doi:10.1007/s12350-021-02563-4.
   PubMed Web of Science ®Google Scholar
• Rettl R, Duca F, Binder C, et al. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Amyloid. 2023;30(1):127–137. doi:10.1080/13506129.2022.2131385.
   PubMed Web of Science ®Google Scholar
• Ternacle J, Bodez D, Guellich A, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(2):126–138. doi:10.1016/j.jcmg.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Duca F, Kammerlander AA, Panzenböck A, et al. Cardiac magnetic resonance T 1 mapping in cardiac amyloidosis. JACC Cardiovasc Imaging. 2018;11(12):1924–1926. doi:10.1016/j.jcmg.2018.06.010.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–819. doi:10.1016/j.jcmg.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Rettl R, Mann C, Duca F, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23(6):767–780. doi:10.1093/ehjci/jeab226.
   PubMed Web of Science ®Google Scholar
• Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1–9. doi:10.1080/13506129.2022.2091985.
   PubMed Web of Science ®Google Scholar